Table 1.
Characteristics of Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.
| All patients |
Not readmitted |
Readmitted |
||
|---|---|---|---|---|
| Characteristic | N = 8023 | N = 7254 | N = 769 | P-value |
| Age at diagnosis, median (IQR) | 57.0 (52.0, 62.0) | 57.0 (52.0, 62.0) | 56.0 (51.0, 61.0) | .087 |
| Sex, N(%) | .300 | |||
| Male | 6264 (78.1%) | 5675 (78.2%) | 589 (76.6%) | |
| Female | 1759 (21.9%) | 1579 (21.8%) | 180 (23.4%) | |
| Race, N(%) | .680 | |||
| White | 5623 (70.1%) | 5081 (70.0%) | 542 (70.5%) | |
| African American | 732 (9.1%) | 657 (9.1%) | 75 (9.8%) | |
| Asian/PI | 483 (6.0%) | 437 (6.0%) | 46 (6.0%) | |
| Hispanic | 926 (11.5%) | 848 (11.7%) | 78 (10.1%) | |
| Other/unknown | 259 (3.2%) | 231 (3.2%) | 28 (3.6%) | |
| Insurance type, N(%) | .890 | |||
| Private | 4469 (55.7%) | 4047 (55.8%) | 422 (54.9%) | |
| Medicaid | 884 (11.0%) | 792 (10.9%) | 92 (12.0%) | |
| Medicare | 2271 (28.3%) | 2057 (28.4%) | 214 (27.8%) | |
| Not insured | 219 (2.7%) | 197 (2.7%) | 22 (2.9%) | |
| Other/unknown | 180 (2.2%) | 161 (2.2%) | 19 (2.5%) | |
| Income ($USD), N(%) | .680 | |||
| <$38 000 | 1435 (17.9%) | 1291 (17.8%) | 144 (18.7%) | |
| $38 000-$47 999 | 1911 (23.8%) | 1741 (24.0%) | 170 (22.1%) | |
| $48 000-$62 999 | 2213 (27.6%) | 1999 (27.6%) | 214 (27.8%) | |
| >$63k | 2464 (30.7%) | 2223 (30.6%) | 241 (31.3%) | |
| No HS diploma, N(%) | .490 | |||
| 21%+ | 1633 (20.4%) | 1493 (20.6%) | 140 (18.2%) | |
| 13-20.9% | 2146 (26.7%) | 1936 (26.7%) | 210 (27.3%) | |
| 7-12.9% | 2491 (31.0%) | 2245 (30.9%) | 246 (32.0%) | |
| <7% | 1753 (21.8%) | 1580 (21.8%) | 173 (22.5%) | |
| Patient urban/rural location, N(%) | .500 | |||
| Metro areas | 6873 (85.7%) | 6211 (85.6%) | 662 (86.1%) | |
| Metro-adjacent | 721 (9.0%) | 656 (9.0%) | 65 (8.5%) | |
| Not metro-adjacent | 315 (3.9%) | 288 (4.0%) | 27 (3.5%) | |
| Rural | 114 (1.4%) | 99 (1.4%) | 15 (2.0%) | |
| Miles to hospital, median (IQR) | 33.5 (12.0, 98.8) | 33.7 (12.0, 98.7) | 32.3 (12.1, 101.2) | .680 |
| Tumor size, N(%) | .180 | |||
| <2 cm | 2229 (27.8%) | 1992 (27.5%) | 237 (30.8%) | |
| 2-5 cm | 4869 (60.7%) | 4424 (61.0%) | 445 (57.9%) | |
| >5 cm | 677 (8.4%) | 617 (8.5%) | 60 (7.8%) | |
| Unknown | 248 (3.1%) | 221 (3.0%) | 27 (3.5%) | |
| AJCC cancer stage, N(%) | .191 | |||
| Stage I | 3629 (45.2%) | 3282 (45.2%) | 347 (45.1%) | |
| Stage II | 3061 (38.2%) | 2776 (38.3%) | 285 (37.1%) | |
| Stage III | 397 (4.9%) | 366 (5.0%) | 31 (4.0%) | |
| Stage IV | 37 (.5%) | 35 (.5%) | 2 (.3%) | |
| Unknown | 899 (11.2%) | 795 (11.0%) | 104 (13.5%) | |
| Charlson-Deyo score, N(%) | <.001 | |||
| 0 | 2772 (34.6%) | 2555 (35.2%) | 217 (28.2%) | |
| 1 | 2428 (30.3%) | 2186 (30.1%) | 242 (31.5%) | |
| 2 | 2823 (35.2%) | 2513 (34.6%) | 310 (40.3%) | |
| Hospital type, N(%) | .059 | |||
| Community cancer programa | 1173 (14.6%) | 1082 (14.9%) | 91 (11.8%) | |
| Academic/research program | 6850 (85.4%) | 6172 (85.1%) | 678 (88.2%) | |
| Facility location, N(%) | <.001 | |||
| New England | 281 (3.5%) | 256 (3.5%) | 25 (3.3%) | |
| Middle Atlantic | 1026 (12.8%) | 883 (12.2%) | 143 (18.6%) | |
| South Atlantic | 1588 (19.8%) | 1466 (20.2%) | 122 (15.9%) | |
| East North Central | 1208 (15.1%) | 1078 (14.9%) | 130 (16.9%) | |
| East South Central | 613 (7.6%) | 557 (7.7%) | 56 (7.3%) | |
| West North Central | 692 (8.6%) | 597 (8.2%) | 95 (12.4%) | |
| West South Central | 1139 (14.2%) | 1067 (14.7%) | 72 (9.4%) | |
| Mountain | 502 (6.3%) | 447 (6.2%) | 55 (7.2%) | |
| Pacific | 974 (12.1%) | 903 (12.4%) | 71 (9.2%) | |
| Nodes resected, N(%) | 2646 (33.0%) | 2376 (32.8%) | 270 (35.1%) | .190 |
| Postoperative length of stay (days), median (IQR) | 8 (6, 13) | 9 (6, 15) | <.0001 |
Abbreviations: AJCC, American Joint Committee on Cancer; HCC, hepatocellular carcinoma.
a
This category includes community programs and comprehensive community programs.